



Department of Defense US Army Medical Research and Materiel Command

Fiscal Year 2001 Prostate Cancer Research Program Awards Book

Table of Contents

Introduction

Fiscal Year 2001 Prostate Cancer Research Program Funded Awards

Infrastructure Awards

Prostate Cancer Consortium Development Awards

Research Awards

Prostate Cancer Clinical Trial Awards

Health Disparity Research – Prostate Scholar Award

Idea Development Awards

New Investigator Awards

Training/Recruitment Awards

Health Disparity Training - Prostate Scholar Awards

Historically Black Colleges and Universities Collaborative Partnership

Awards

Postdoctoral Traineeship Awards

Fiscal Year 2001 Prostate Cancer Research Program Participants

Peer Reviewers

Integration Panel Members

Ad Hoc Programmatic Reviewers

Glossary of Terms

Introduction

The US Army Medical Research and Materiel Command (USAMRMC) is pleased to present the award list of funded projects for its fiscal year 2001 (FY01) Prostate Cancer Research Program (PCRP). Award negotiations were completed on September 30, 2002. The awards listed in this document were selected by a competitive two-tiered review process. Funding decisions were based on evaluations of scientific excellence in the first review tier, followed by determinations of programmatic relevance in the second tier. These projects represent a diverse portfolio of scientific research in three categories: (1) Research Awards, (2) Training/Recruitment Awards, and (3) Infrastructure Awards.

Congress directed \$100 million in appropriations for prostate cancer research in FY01. Following receipt of funds, a programmatic strategy was developed, proposals were solicited and evaluated, awards were selected, and contract negotiations were completed. A total of 209 studies was funded.

The programmatic strategy implemented in the FY01 PCRP called for proposals in prostate cancer research in two separate Program Announcements. The Research Award category includes New Investigator and Idea Development Awards in Program Announcement I, released December 13, 2000. New Investigator Awards are targeted to investigators in the early phases of their careers and to investigators established in other fields who desire to move into prostate cancer research but who have little or no preliminary data in prostate cancer. Idea Development Awards are aimed at giving established prostate cancer investigators and investigators who want to move into prostate cancer research and who have preliminary data relevant to prostate cancer the necessary support and time to undertake underinvestigated areas of research. Idea Development Awards are designed to encourage innovative approaches to prostate cancer research from established investigators who are at, or above the level of assistant professor or equivalent. This award is intended to help the investigator continue to pursue, or enter into the field of prostate cancer research. Program Announcement II, released February 14, 2001, requested proposals in two newly established Research Award categories. Health Disparity Research – Prostate Scholar Awards are intended to encourage scientists or physicians who have postdoctoral and/or fellowship training, but are not yet established researchers, to focus their research efforts on the disparate burden of prostate cancer in African Americans. Prostate Cancer Clinical Trial Awards are intended to fund prospective Phase I or Phase II clinical trials in the areas of prostate cancer therapy, diagnosis, detection, and prevention.

The Training/Recruitment Award category includes Postdoctoral Traineeship Awards from Program Announcement I, Health Disparity Training – Prostate Scholar Awards, and Historically Black Colleges and Universities (HBCU) Collaborative Partnership Awards from Program Announcement II. Postdoctoral Traineeship Awards provide support for recent doctoral degree graduates to gain experience in prostate cancer research. Health Disparity Training – Prostate Scholar Awards are intended to provide investigators in the early stages of their careers with mentored training opportunities that focus on the disparate burden of prostate cancer in African Americans. HBCU Collaborative Partnership Awards are institutionally based awards directed at HBCU that are intended to intensify the commitment of the prostate cancer research

community to investigate the disparate burden of prostate cancer in African American men and increase the number of HBCU scientists who are trained as prostate cancer researchers.

The Infrastructure Award category consists of the Prostate Cancer Consortium Development Award, the first part of a two-part award working toward the Prostate Cancer Consortium Award. The intent of the Prostate Cancer Consortium Award is to develop a major, coordinated, goal/product-driven research effort that involves the nation's leading prostate cancer researchers and focuses on an overarching problem relevant to the prevention, detection, diagnosis, treatment, or cure of prostate cancer. Unlike other mechanisms within the PCRCP, the Consortium Award will be executed through two separate awards, the Prostate Cancer Consortium Development Award in FY01 and the Prostate Cancer Consortium Award in FY02.

As the funded scientists embark on these projects, the Department of Defense and the US Army gratefully acknowledge the participation of their scientific, clinical, and consumer advisors. The expertise, vision, and diversity of perspectives of all individuals who contributed to this program were vital to developing a sound investment strategy on behalf of all persons affected by prostate cancer. It is with great anticipation and excitement that the USAMRMC awaits the outcomes of these research projects

Consortium Development Awards

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Award Amount
PC012011	Arap	Wadih	University of Texas M.D. Anderson Cancer Center	A Comprehensive Mechanism-Based Approach for Diagnosis and Treatment of Prostate Cancer	\$135,000
PC012007	Ho	Shuk-Mei	University of Massachusetts Medical School	Estrogens and Antiestrogens in Prostate Cancer	\$149,480
PC012004	Mohler	James	University of North Carolina at Chapel Hill	Racial Differences in Prostate Cancer: Influence of Health Care Interaction and Host and Tumor Biology	\$150,000
PC012006	Pestell	Richard	Albert Einstein College of Medicine	Signal Transduction-Based Mouse Model of Prostate Cancer	\$124,606
PC012003	Simons	Jonathan	Emory University	A Synergy Consortium Targeting the Lethal Phenotypes of Prostate Cancer	\$150,000

Clinical Trial Awards

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Award Amount
PC011011	Chi	Kim	University of British Columbia	A Phase I/II Study of Combination Neoadjuvant Hormone Therapy and Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior to Radical Prostatectomy in Patients with Localized Prostate Cancer	\$809,400
PC011010	Dipaola	Robert	Cancer Institute of New Jersey	A Phase I/II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer	\$634,254
PC011029	Hall	Simon	Mount Sinai School of Medicine	Phase I Trial of Adenovirus-Mediated IL-12 Gene Transduction in Patients with Radiorecurrent Prostate Cancer	\$960,904
PC011020	Kwon	Eugene	Loyola University Chicago	A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer	\$2,483,087
PC011015	Sokoloff	Mitchell	University of Chicago	Neoadjuvant Anti-Angiogenesis Therapy for Prostate Cancer	\$1,125,152

Health Disparity Research - Prostate Scholar Award

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Award Amount
PC011024	Price	Marva	Duke University School of Nursing	Increasing Sustained Participation in Free Mass Prostate Cancer Screening Clinics	\$406,421

Idea Development Awards

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Award Amount
PC010180	Adam	Bao-Ling	Eastern Virginia Medical School	Protein BioChip Mass Spectrometry: A Novel Protein Profiling Approach for Diagnosis and Prognosis of Prostate Cancer	\$488,544
PC010186	Arap	Wadih	University of Texas M.D. Anderson Cancer Center	Probing Surface Heterogeneity of Metastatic Prostate Cancer Cells	\$541,383
PC010507	Baker, Jr.	James	University of Michigan	Targeting Chemotherapeutic Drugs to Prostate Cancer Cells Using Dendrimers Coupled to Anti-PSMA Antibody	\$563,589
PC010634	Baranowska-Kortylewicz	Janina	University of Nebraska Medical Center	Antigen-Independent Methods to Improve Radioimmunotherapy of Prostate Cancer	\$537,084
PC010458	Belldegrun	Arie	University of California, Los Angeles School of Medicine	Molecular Characterization of Androgen Independence to Delay Progression to Hormone Refractory Prostate Cancer	\$572,214
PC010536	Bonavida	Benjamin	University of California, Los Angeles	Regulation of TRAIL-Mediated Apoptosis in Prostate Cancer by Overexpression of XIAP	\$572,292
PC010523	Brown	Edward	Brigham and Women's Hospital	Ca ²⁺ Receptor, Prostate Cancer, and Bone Metastases	\$634,338
PC010541	Buchsbaum	Donald	University of Alabama at Birmingham	Genetic Radiotherapy of Prostate Cancer	\$322,875
PC010667	Buehrer	Benjamin	Karo Bio USA, Incorporated	Conformational Peptide Probes for Drug Discovery in Prostate Cancer	\$375,000
PC010174	Burnstein	Kerry	University of Miami, School of Medicine	Rho Family GTPases-Key Regulators of Prostate Cancer Cell Cycle Progression and Tumorigenesis	\$568,087
PC020177	Carey	Michael	University of California, Los Angeles	Interrogating Androgen Receptor Mediated Gene Expression and Tumor	\$571,875
PC010217	Cavalieri	Ercole	University of Nebraska Medical Center	Role of Estrogen Metabolism in the Initiation of Prostate Cancer: Biomarkers of Susceptibility and Early Detection	\$503,783
PC010489	Chai	Karl	University of Central Florida	Prostasin's Role in Prostate Cancer	\$506,795
PC010555	Chang	Chawnsiang	University of Rochester	Suppression of Androgen Receptor Transactivation by Akt Kinase	\$598,125
PC010114	Chen	Ching-Shih	The Ohio State University	New Drug Design for Prostate Cancer	\$552,348

New Investigator Awards

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Award Amount
PC010227	Algan	Ozer	University of Arizona	Dynamic Tissue Culture System from Prostate Biopsy Specimens as a Model for Predicting Tumor	\$336,571
PC010326	Bai	Wenlong	University of South Florida	Mechanism of Androgen Protection of Prostate Cancer Cell Apoptosis	\$326,250
PC010692	Basilion	James	Massachusetts General Hospital East CMIR	Non-Invasive Imaging of Gene Expression in Prostate Tumors	\$272,134
PC010591	Baum	Linda	University of California, Los Angeles School of Medicine	Elucidation of a Novel Cell Death Mechanism in Prostate Epithelial Cells	\$343,395
PC010566	Britt	Deborah	Rhode Island Hospital	Examination of a Novel Protein, LYRIC, and Its Involvement in Prostate Tumor Suppression Mediated by the Cell Adhesion Molecule CEACAM1-L	\$342,377
PC010583	Cao	Jian	State University of New York at Stony Brook	Examination of the Unique Role of Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) in Prostate Cancer Invasion and Metastasis	\$338,626
PC010661	Carmody	James	University of Massachusetts	A Holistic Quality of Life Intervention for Patients with Secondary Prostate Cancer	\$356,045
PC010285	Chakravarty	Prabir	Albert Einstein College of Medicine	Targeting Radiation Therapy for Developing Dendritic Cell-Based Immunotherapy of Metastatic Prostate Cancer	\$374,151
PC010333	Cheng	Linzhao	Johns Hopkins University	Antigen-Specific Immunotherapy Using Lentivirus-Transduced Hematopoietic Progenitor Cells: A Novel Approach for the Treatment of Metastatic Prostate Cancer	\$122,625
PC010163	Counter	Christopher	Duke University Medical Center	Inhibition of Telomerase as a Therapeutic Target for the Treatment of Prostate Cancer	\$346,500
PC010645	Crespo	Carlos	State University of New York at Buffalo	Prostate Cancer Mortality in Puerto Rican Men: The Effect of Body Habitus and Physical Activity	\$348,169
PC010264	Cristiano	Richard	University of Texas M.D. Anderson Cancer Center	Targeting Gene Delivery to Prostate Tumor and Tumor Vasculature	\$330,475
PC010551	Emelianov	Stanislav	University of Michigan	Prostate Carcinoma Detection Using Combined Ultrasound, Elasticity, and Tissue Strain-Hardening Imaging	\$348,985
PC010025	Eng	Charis	The Ohio State University	Genetic Alterations in Epithelial and Stromal Compartments of Prostate Adenocarcinomas	\$331,876

PC010424	Fowke	Jay	University of South Carolina	Molecular Markers of Estrogen Metabolism and Progression from High-Grade Prostatic Intraepithelial Neoplasia (HG PIN) to Prostate Cancer	\$339,937
PC010240	Goldman	Radoslav	Lombardi Cancer Center, Georgetown University Medical Center	Mutagen Sensitivity, Apoptosis, and Polymorphism in DNA Repair as Measures of Prostate Cancer Risk	\$348,509
PC010449	Gregory	Christopher	University of North Carolina at Chapel Hill	The Role of Nuclear Receptor Coactivators in Recurrent Prostate Cancer	\$327,131
PC010599	Griffith	Thomas	University of Iowa	Treatment of Prostate Cancer with TRAIL/Apo-2L Encoding Recombinant Adenovirus	\$330,750
PC010257	Grigsby	James	University of Colorado Health Sciences Center	Effects of Androgen Blockade on Cognitive Function and Quality of Life in Men with Prostate Cancer	\$281,576
PC010071	Hayward	Simon	Vanderbilt University Medical Center	Paracrine Regulation of Prostatic Carcinogenesis	\$339,701
PC010406	Hediger	Matthias	Brigham and Women's Hospital	Membrane Transporters in Prostate Cancer Development	\$381,375
PC010134	Helgason	Cheryl	British Columbia Cancer Agency	Mechanisms of Prostate Tumor Cell-Mediated Immunosuppression: Examination of Dendritic Cell Survival, Maturation, and Function in Response to Prostate Cancer	\$224,255
PC010454	Hinshaw	Jerald	University of Utah	Synthesis of Lipoprotein Immunostimulants for Treating Prostate Cancer	\$336,793
PC010286	Holt	Shawn	Virginia Commonwealth University	Molecular Mechanisms of Prostate Cancer Progression	\$320,702
PC010197	Hong	Junyan	University of Medicine Dentistry of New Jersey	Interindividual Variation in the Metabolic Activation of Heterocyclic Amines and Susceptibility to Prostate Cancer	\$358,799
PC010531	Iwamoto	Yoshiki	Medical College of Wisconsin	Testosterone-Independent Cell Growth Mediated by IL-6-STAT3 Pathway in Prostate Cancer Cells	\$337,457
PC010476	Jarrard	David	University of Wisconsin	Relaxation of Insulin-Like Growth Factor II Imprinting in Prostate Cancer Development	\$327,375
PC010137	Jayadevappa	Ravishankar	University of Pennsylvania	Quality of Life and Cost of Care of Prostate Cancer Patients	\$356,335
PC010162	Jhiang	Sissy	The Ohio State University	Sodium Iodide Symporter Gene Transfer for Imaging and Ablation of Prostate Cancer	\$331,656
PC010614	Johnson-Pais	Teresa	University of Texas Health Science Center	Identification of a Gene on Chromosome 18Q21 Involved in Suppressing Metastatic Prostate Cancer	\$323,043

PC010563	Knudsen	Beatrice	Cornell Medical College	Hepatocyte Growth Factor and Interleukin-6 in Prostate Cancer Bone Metastasis	\$381,375
PC010016	Knudsen	Karen	University of Cincinnati	Deregulation of Cyclin E and BRG-1 in Prostate Cancer	\$332,291
PC010654	Koeneman	Kenneth	University of Texas Southwestern Medical Center at Dallas	Targeting Orthotopic and Osseous Prostate Cancer Xenografts with Selective, Systemic Telomerase Inhibition	\$339,392
PC010503	Krasnykh	Victor	University of Alabama at Birmingham	Derivation of Double-Targeted Adenovirus Vectors for Gene Therapy of Prostate Cancer	\$322,875
PC010343	Kulik	George	University of Virginia	Anti-Apoptotic Signaling in Prostate Cancer Cells	\$332,859
PC010490	Kurzer	Mindy	University of Minnesota	Dietary Phytoestrogens and Prostate Cancer Prevention	\$324,390
PC010047	Lentsch	Alex	University of Louisville	Chemokines and Prostate Tumor Growth	\$313,998
PC010062	Lewis	Michael	University of Missouri, Columbia	Pretargeted Radiolanthanides for Prostate Tumor Therapy	\$320,261
PC010651	Li	Chuan-Yuan	Duke University Medical Center	Enhancement of Prostate Cancer Radiotherapy by Immunogene Therapy	\$346,500
PC010201	Lindholm	Paul	Medical College of Wisconsin	RhoA, NF-kB, and Prostate Cancer Cell Invasion	\$336,458
PC010496	Liu	Mingyao	Texas A&M University System Health	Role of a Novel Prostate Specific G-Protein Coupled Receptor (PSGR) in Prostate Tumor Development	\$327,375
PC010394	Liu	Wanguo	Mayo Clinic	CHK2, a Candidate Prostate Cancer Susceptibility Gene	\$321,750
PC010546	Lowell	Clifford	University of California	Mechanisms of Prostate Cancer Bone Metastasis	\$340,125
PC010267	Ludewig	Gabriele	University of Kentucky	Prostate Cancer Risk through Exposure to Halogenated Hydrocarbons and Modulation by Dietary Supplementation	\$325,790
PC010058	Lyles	Douglas	Wake Forest University School of Medicine	Selective Killing of Prostate Tumor Cells by Cytocidal Viruses	\$322,657
PC010671	Minev	Boris	University of California, San Diego	A New Target for Immunotherapy of Prostate Cancer	\$228,000
PC010342	Nikitin	Alexander	Cornell University	Modeling Prostate Cancer by Conditional Inactivation of p53 and Rb	\$356,092

PC010194	Ove	Roger	University of Alabama at Birmingham	Prostate Brachytherapy with Concurrent Delivery of Conditionally Replicative Adenovirus (CRAD)	\$159,463
PC010112	Pan	Dongfeng	University of Virginia	Nuclear Imaging for Assessment of Prostate Cancer Gene Therapy	\$320,489
PC010304	Pili	Roberto	Johns Hopkins University	Modulation of Prostate Tumor Cell Response to Retinoids by Chromatin-Remodeling Agents: Role of the Retinoic Acid Receptor Beta (RAR-Beta)	\$367,875
PC010297	Pohar	Kamal	Memorial Sloan-Kettering Cancer Center	Role of Reactive Oxygen Species in Cavernous Nerve Damage following Radical Prostatectomy	\$330,735
PC010588	Quinn	Timothy	University of California at San Francisco	Killing Prostate Cancer Cells and Endothelial Cells with a VEGF-Triggered Cell Death Receptor	\$329,525
PC010077	Riese	David	Purdue University	Regulation of Prostate Tumor Cell Line Proliferation and Tumorigenicity by the ErbB4 Receptor Tyrosine Kinase	\$335,664
PC010300	Safavy	Ahmad	University of Alabama at Birmingham	Paclitaxel-Monoclonal Antibody Conjugates for Targeted Therapy of Prostate Cancer	\$322,875
PC010577	Sakamuro	Daitoku	Purdue University	Role of Bin1 in Cellular Senescence and Apoptosis by E2F1 in Androgen-Independent Prostate Cancer Cells	\$337,500
PC010070	Sang	Qing-Xiang	Florida State University	Endometase in Androgen-Repressed Human Prostate Cancer	\$328,500
PC010095	Schmittgen	Thomas	Washington State University	Aptamer-Drug Conjugates for Prostate Cancer Therapy	\$317,464
PC010460	Singal	Rakesh	Overton Brooks VA Medical Center	Methylation-Mediated Repression of Selected Genes in Prostate Cancer	\$220,617
PC010687	Smith	Jeffrey	University of Alabama at Birmingham	New Antitumor Agents to Combat the Subversion of Apoptotic Cell Death in Prostate Cancer	\$322,875
PC010395	Srivastava	Rakesh	University of Maryland	Intracellular Mechanism and Clinical Significance of TRAIL in Prostate Cancer	\$266,918
PC010718	Sweeney	Christopher	Indiana University	Targeting Nuclear Factor Kappa B for the Treatment of Prostate Cancer	\$335,250
PC010390	Tang	Careen	Georgetown University Medical Center	A Novel Molecular Targeting of a Tumor-Specific Oncogenic Mutant Receptor in Human Prostate Cancer	\$349,200
PC010504	Tolcher	Anthony	Cancer Therapy and Research Center	Predictive Biomarkers of Response to Bcl-2 Biomodulation by G3139 and Docetaxel in Hormone-Refractory Prostate Cancer	\$325,771
PC010256	Truica	Cristina	Georgetown University	The Role of (beta)-Catenin in Androgen Receptor Signaling	\$349,200

PC010159	Wadkins	Randy	Johns Hopkins University School of Medicine	Temporal and Spatial Dynamics of DNA Topoisomerase I in Prostate Cancer	\$367,875
PC010234	Watkins Bruner	Deborah	Fox Chase Cancer Center	Preferences and Utilities for Prostate Cancer Screening and Treatment: Assessment of the Underlying Decision-Making Process	\$394,740
PC010268	Whalen	Janey	University of Pittsburgh	Peptide-Mediated Transduction of Proteins and Nucleic Acids to Prevent and Treat Experimental Prostate Cancer	\$324,368
PC010066	Xiang	Rong	The Scripps Research Institute	Novel Combination Therapy for Prostate Carcinoma	\$398,925
PC010516	Zhu	Yuan Shan	Cornell University Weill Medical College	Dietary Fat, Sex Hormones, IGF, and Prostate Cancer	\$381,324

PC010674	Cher	Michael	Wayne State University	Creation of a Bone Environment Hostile to Prostate Cancer	\$552,148
PC010497	Chirgwin	John	University of Texas Health Sciences Center	PSA Converts Parathyroid Hormone-Related Protein (PTHrP) from an Osteolytic to an Osteoblastic Factor: Role in Bone Metastasis	\$540,110
PC010324	Claessens	Frank	University of Leuven	The Hinge Region as a Key Regulatory Element of Androgen Receptor Dimerization, DNA Binding, and Transactivation	\$201,930
PC010308	Coyne	James	University of Pennsylvania	Hot Flashes among Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Psychosocial and Quality of Life Issues	\$584,635
PC010660	Defranco	Donald	University of Pittsburgh	Novel Coactivators for Androgen Receptor	\$544,273
PC010110	Denmeade	Samuel	Johns Hopkins University	Enzymatic Activation of Peptide Prodrugs by Prostate-Specific Membrane Antigen (PSMA) as Targeted Therapy for Prostate Cancer	\$591,543
PC010404	Derenzo	Stephen	EO Lawrence Berkeley National Laboratory	Compact Positron Tomograph for Prostate Imaging	\$583,897
PC010513	Ellis	Thomas	Loyola University School of Medicine	Effects of Androgen Ablation on Anti-Tumor Immunity	\$523,955
PC010352	Erhardt	Paul	The University of Toledo College of Pharmacy	PAM Inhibitors	\$532,500
PC010225	Feldman	David	Stanford University	Vitamin D Treatment of Prostate Cancer: The Inhibitory Role of IGFBP-3	\$588,750
PC010149	Fisher	Paul	Columbia University	Strategies for Selectively Eradicating Prostate Cancer Cells	\$414,881
PC010427	Fleischmann	William	University of Texas Medical Branch	Novel Tumor Vaccine for Prostate Cancer	\$558,750
PC010353	Freeman	Michael	Children's Hospital Boston	The Calcium Channel CaT1 in Prostate Cancer Progression	\$590,907
PC010239	Garen	Alan	Yale University	Targeting the Tumor Vasculature for Prostate Cancer Immunotherapy	\$351,310
PC010281	Gelmann	Edward	Georgetown University	Genetic Risk Factor for Prostate Cancer	\$581,875
PC010477	Gewirth	Daniel	Duke University Medical Center	Structural and Functional Analysis of Androgen Receptor-DNA Interactions	\$533,841

PC010501	Ghosh	Jagadananda	University of Virginia	Role of Dietary Fat in Prostate Carcinogenesis	\$360,380
PC010719	Gill	Inderbir	Cleveland Clinic Foundation	Development of a Robotic-Enhanced Technique of Laparoscopic Radical Prostatectomy	\$325,772
PC010347	Gorelik	Elieser	University of Pittsburgh Cancer Institute	A Novel Approach in Prostate Cancer Therapy	\$541,710
PC010321	Gudas	Lorraine	Weill Medical College of Cornell University	Retinoids and Histone Deacetylase Inhibitors in the Treatment of Prostate Cancer	\$635,625
PC010358	Gunatilaka	Leslie	University of Arizona	Isolation, Characterization, and Evaluation of Anti-Prostate Cancer Agents of PC SPES, a Clinically Effective Alternative Therapy for Advanced Prostate Cancer	\$520,220
PC010081	Hale	Laura	Duke University Medical Center	Zinc Alpha2- Glycoprotein and Cachexia in Prostate Cancer	\$577,497
PC010269	Hauser	Craig	The Burnham Institute	Gene Targets in Prostate Tumor Cells That Mediate Aberrant Growth and Invasiveness	\$491,200
PC010319	Hemstreet	George	University of Oklahoma Health Sciences Center	Biomarker-Based Individual Risk Assessment for Prostate Cancer	\$529,990
PC010131	Jin	Qing	The Scripps Research Institute	High Throughput Synthesis and Screening for Agents Inhibiting Androgen Receptor-Mediated Gene Transcription	\$691,393
PC010023	Joiner	Michael	Gray Laboratory Cancer Research Trust	Enhanced Cell Killing by Very Low Dose-Rate Irradiation: Possibilities for Better Prostate Cancer Radiotherapy	\$553,714
PC010211	Jones	Graham	Northeastern University	Prostate-Activated Prodrugs and Imaging Agents	\$547,632
PC010155	Josephson	Lee	Massachusetts General Hospital	An MR Contrast Agent for Intra-Prostatic Imaging of Prostatic Cancer	\$644,143
PC010401	Jung	Mira	Georgetown University	Development of an Interstitial Gene Delivery for Prostate Tumor Radiosensitization	\$582,000
PC010505	Karczmar	Gregory	University of Chicago	Angiogenesis and Invasiveness in Prostate Cancer Detected with High Spectral and Spatial Resolution Magnetic Resonance Imaging	\$550,087
PC010250	Killary	Ann	University of Texas M.D. Anderson Cancer Center	Functional Mapping and Identification of a Prostate Cancer Tumor Suppressor Gene within Chromosome 3P	\$561,778
PC010219	Kittles	Rick	National Human Genome Center at Howard University	SNP Analysis of Candidate Genes for Prostate Cancer in African Americans	\$500,050

PC010456	Klostergaard	Jim	University of Texas M.D. Anderson Cancer Center	Novel Paclitaxel Copolymer for Treatment of Androgen-Independent Prostate Cancer Bone Metastases	\$562,500
PC010520	Kung	Hsing-Jien	University of California, Davis	Neuropeptides, Tyrosine Kinases, and Prostate Cancer	\$555,597
PC010475	Kuo	Calvin	Stanford University	Development of Gutless Adenoviral Vectors Encoding Anti-Angiogenic Proteins for Therapy of Prostate Cancer	\$587,804
PC010004	Lamartiniere	Coral	University of Alabama at Birmingham	Dietary Genistein and Prostate Cancer Chemoprevention	\$511,623
PC010146	Lee	Jiing Dwan	The Scripps Research Institute	Regulatory Mechanism of EGFR-Mediated Oncogenic Signaling in Prostate Cancer Cells	\$497,006
PC010633	Link, Jr.	Charles	Human Gene Therapy Research Institute	Transcomplementing Adenoviral Vectors to Deliver the Sodium/Iodide Symporter Gene	\$428,013
PC010436	Lokeshwar	Vinata	University of Miami School of Medicine	Hyaluronic Acid and Hyaluronidase in Prostate Cancer: Evaluation of Their Therapeutic and Prognostic Potential	\$565,550
PC010699	Lu	Junxuan	AMC Cancer Research Center	Methylselenium and Prostate Cancer Apoptosis	\$633,750
PC010277	Lu	Michael	Brigham and Women's Hospital	Caveolin-1 Modulates Androgen Receptor Signaling in Advanced Prostate Cancer	\$625,592
PC010096	Luduena	Richard	University of Texas Health Science Center	The Role of the (Beta)II Isotype of Tubulin in the Diagnosis and Development of Prostate Cancer	\$286,865
PC020761	Martignetti	John	Mount Sinai School of Medicine	Targeted Molecular Analysis of a Familial Prostate Cancer Susceptibility Gene	\$635,625
PC010435	McCarthy	James	University of Minnesota	Hyaluronan Biosynthesis in Prostate Carcinoma	\$556,872
PC010431	Miller	Duane	University of Tennessee	Selective Cytotoxic Phospholipids for Prostate Cancer	\$556,364
PC010075	Mincheff	Milcho	George Washington University	Naked DNA Immunization for Prevention of Prostate Cancer in a Dunning Rat Prostate Tumor Model	\$570,000
PC010340	Mohler	James	University of North Carolina at Chapel Hill	Prevention of Development of Recurrent Growth of Prostate Cancer	\$545,453
PC010403	Murphy	Brian	SRI International	The Nuclear Receptor PPAR(delta), a New Therapeutic Target for Inhibition of Prostate Cancer Progression	\$374,661
PC010537	Omdahl	John	University of New Mexico	Prostate Cancer and Repression of Cytochrome P450c1 Gene Expression	\$500,825

PC010237	Peehl	Donna	Stanford University	Development of a Novel Tissue Slice Culture Model of Human Prostate Cancer	\$587,211
PC010696	Pelizzari	Charles	University of Chicago	Image Guidance and Assessment of Radiation-Induced Gene Therapy	\$553,642
PC010693	Pienta	Kenneth	University of Michigan	Biological Differences between Prostate Cancer Cells That Metastasize to Bone versus Soft Tissue Sites	\$566,250
PC010461	Rajasekaran	Ayyappan	University of California, Los Angeles	Analysis of Microtubule-Mediated Functions of Prostate-Specific Membrane Antigen	\$572,197
PC010717	Reddi	A Hari	University of California, Davis	Bone Morphogenetic Proteins, Antagonists, and Receptors in Prostate Cancer	\$548,969
PC010083	Reiter	Robert	University of California	Mechanisms and Refinements of PSCA-Directed Antibody Therapy	\$569,197
PC010030	Ritter	Mark	University of Wisconsin	Molecular Markers and Prostate Cancer Radiation Response	\$329,345
PC010273	Roberts	Charles	Oregon Health Sciences University	IGF-Regulated Genes in Prostate Cancer	\$534,407
PC010659	Robins	Diane	University of Michigan Medical School	Humanizing the Mouse Androgen Receptor to Study Polymorphisms and Mutations in Prostate Cancer	\$532,842
PC011007	Russell	Pamela	Washington University	Evaluation of Laproscopic Radical Prostatectomy for the Treatment of Localized Prostate Cancer	\$522,000
PC010079	Russell	Pamela	Prince of Wales Hospital	The Role of p53 Mutations in Metastasis of Prostate Cancer to Bone	\$456,840
PC010522	Safe	Stephen	Texas A&M University	Inhibitory Ah Receptor-Androgen Receptor Crosstalk in Prostate Cancer	\$436,500
PC010242	Sercarz	Eli	La Jolla Institute for Allergy and Immunology	Potential of the Endogenous Immune Response to Prostate Cancer Antigens	\$689,456
PC010571	Sillerud	Laurel	University of New Mexico	Non-Invasive Diagnosis of Androgen Sensitivity in Human Prostate Tumors	\$542,745
PC010677	Slate	Elizabeth	Medical University of South Carolina	Statistical Methods for Enhanced Inference from Longitudinal Biomarkers for Prostate Cancer	\$337,054
PC010463	Slawin	Kevin	Baylor College of Medicine	Induced CD40 Activation in Dendritic Cell-Based Prostate Cancer Vaccines	\$564,375
PC010325	Smith	Nadine	Pennsylvania State University	Optimized Hyperthermia Treatment of Prostate Cancer Using a Novel Intracavitary Ultrasound Array	\$521,767
PC010152	Soleimani-Meigooni	Ali	University of Kentucky	Methods of Dosimetry and Treatment Planning for Second Generation Linear Sources	\$543,000

PC010392	Spiegel	Sarah	Georgetown University Medical Center	Lysophosphatidic Acid Regulation and Roles in Human Prostate Cancer	\$583,029
PC010017	Srivastava	Shiv	Center for Prostate Disease Research	Characterization of a Prostate Specific G-Protein Coupled Receptor (PSGR) in Prostate Cancer	\$426,857
PC010506	Sun	Leon	Center for Prostate Disease Research	Development of Internet-Accessible Prediction Models for Prostate Cancer Diagnosis, Treatment, and Follow-up	\$412,646
PC010690	Sun	Zijie	Stanford University	Interaction between a Novel p21-Activated Kinase (Pak6) and Androgen Receptor in Prostate Cancer	\$294,374
PC010091	Sytkowski	Arthur	Beth Israel Deaconess Medical Center	Trace Elements and the Development of Prostate Cancer	\$637,437
PC010617	Taichman	Russell	University of Michigan Dental School	Molecular Mechanisms of Prostate Cancer Metastasis	\$562,436
PC010552	Talcott	James	The General Hospital Corporation	Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer	\$633,403
PC010684	Taylor	Kathryn	Georgetown University	Treatment Decision Making in Early-Stage Prostate Cancer: Evaluation of Computer-Based Patient Education and an Interactive Decision Aid	\$580,713
PC010459	Tenniswood	Martin	University of Notre Dame	Apoptosis and Tumor Progression in Prostate Cancer	\$557,493
PC010078	Terrian	David	Brody School of Medicine East Carolina University	Translational Hyperactivity as a Target for Prostate Cancer Therapy	\$330,065
PC010468	Thompson	Timothy	Baylor College of Medicine	In Situ Gene Therapy for Prostate Cancer: Development of Systemic Anti-Tumor Immunity	\$543,381
PC010698	Tsui	Benjamin	University of North Carolina at Chapel Hill	Corrective In-111 Capromab Pendetide SPECT Image Reconstruction Methods for Improved Detection of Recurrent Prostate Cancer	\$530,468
PC010092	Ukoli	Flora	Howard University Cancer Center	Dietary Fat and Vitamin E in Prostate Cancer Risk among African Americans and West Africans: A Case-Control Study	\$553,628
PC010148	Vijayakumar	Srinivasan	University of Illinois at Chicago	Prevention of Post-Radiotherapy Failure in Prostate Cancer by Vitamin D	\$454,211
PC010381	Wang	Zhou	Northwestern University Medical School	Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models	\$537,189
PC010665	Weichselbaum	Ralph	University of Chicago	Targeted Inhibition of DNA Repair in Prostate Cancer Therapy	\$489,253

PC010228	Weigel	Nancy	Baylor College of Medicine	The Role of Androgen Receptors in Androgen-Independent Prostate Cancer	\$554,326
PC010375	Weinstein	I.	Columbia University	Interactions between Cell Cycle Control Proteins and the Androgen Receptor in Prostate Cancer	\$613,125
PC010480	Wilding	George	University of Wisconsin	Understanding Molecular Mechanisms of Androgen-Induced Oxidative Stress for Chemoprevention of Prostate Cancer	\$534,115
PC010039	Zhang	Jian-Ting	Indiana University	Translational Regulation of PTEN/MMAC1 Expression in Prostate Cancer	\$558,731

Health Disparity Training - Prostate Scholar Awards

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Award Amount
PC011004	Freedman	Matthew	Massachusetts General Hospital	A Large-Scale Genomic Approach to Prostate Cancer Risk in African American Men	\$300,000
PC011030	Powel	Lorrie	Edith Nourse Rogers Memorial Veterans Hospital	Incontinence Morbidity following Radical Prostatectomy: Psychosocial Impact on African American and White Men	\$147,000

Historically Black Colleges and Universities Collaborative Partnership Awards

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Award Amount
PC011023	Bagasra	Omar	Clafin University	Role of Zinc in the Pathogenesis of Prostate Cancer	\$408,351
PC011008	Williams	Myron	Clark Atlanta University	Biomarkers for Metastatic Prostate Cancer	\$803,300

Postdoctoral Traineeship Awards

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Award Amount
PC010433	Allen	Naomi	Imperial Cancer Research Fund	A Case-Control Study of Selenium in Finger Nails and the Risk of Prostate Cancer	\$74,600
PC010361	Boileau	Thomas	The Ohio State University	Antioxidant Therapy for Men with Asymptomatic Prostate Cancer	\$97,902
PC010678	Briknarova	Klara	The Burnham Institute	Molecular Study of BAG Domains: A New Motif in Prostate Cancer	\$97,994
PC010538	Chandra	Dhyan	University of Texas M.D. Anderson Cancer Center	A Novel Mitochondria-Dependent Apoptotic Pathway (MAP) in Prostate Cancer (PCa) Cells	\$98,000
PC010135	Chen	Charlie	University of California, Los Angeles School of Medicine	Role of Androgen Receptor in Growth of Androgen Independent Prostate Cancer	\$97,932
PC010413	Dong	Xiangyang	Mayo Clinic	Analysis of Human AXIN2 and Other Wnt Signal Pathway Genes in Human Prostate Cancer	\$98,000
PC010055	Dong	Yan	Roswell Park Cancer Institute Corporation	Biomarkers of Selenium Chemoprevention of Prostate Cancer	\$97,976
PC010448	Fei	Baowei	Case Western Reserve University	Molecular Imaging for IMRI-Guided Minimally Invasive Treatment of Prostate Cancer	\$97,982
PC010575	Gery	Sigal	Cedars-Sinai Medical Center	TMEFF2: A Novel Gene Expressed Selectively in Androgen-Responsive Prostate Cancers	\$98,000
PC010488	Gulley	James	National Cancer Institute	A Randomized Phase II Study of a PSA-Based Vaccine in Patients with Localized Prostate Cancer Receiving Standard Radiotherapy	\$44,508
PC010251	Huang	Wen-Xin	Georgetown University	Gene Methylation in Prostate Cancer	\$90,277
PC010111	Khoury	Joseph	Children's Hospital	Regulation of ErbB Receptor Signaling through a Caveolae-like Membrane Microdomain in Prostate Cancer	\$98,000
PC010559	Lee	Sunyoung	University of California, Los Angeles	Mechanisms of VEGF Availability in Prostate Cancer	\$97,932
PC010350	Li	Xin	Cleveland Clinic Foundation	Investigation of SNARE-Mediated Membrane Trafficking in Prostate Cancer Cells	\$97,989
PC010214	Liu	Zesheng	Baylor College of Medicine	Prostate Specific Expression of Maspin in a Transgenic Mouse Model: Implications in Prostate Carcinogenesis	\$97,990
PC010338	Maceyka	Michael	Georgetown University Medical Center	Regulation of Sphingosine Kinase in Prostate Cancer Cells	\$97,906

PC010384	Manes	Thomas	Yale University School of Medicine	Role of (alpha)v(Beta)3 Integrin in the Establishment and Growth of Metastatic Lesions in Prostate Cancer	\$98,000
PC010430	Salm	Sarah	New York University School of Medicine	The Isolation and Characterization of Prostate Stem Cells	\$98,000
PC010562	Sansal	Isabelle	Dana-Farber Cancer Institute	The Role of the Forkhead Complexes in Suppressing Prostate Epithelial Cell Transformation	\$98,000
PC010499	Sardar	Vineet	University of Memphis	Computational Modeling of the Prostate-Expressed Lysophosphatidic Acid Receptor Edg-7	\$98,000
PC010482	Schwarze	Steven	University of Wisconsin-Madison	Role of Cdc37 in Overcoming p16 Mediated Growth Arrest in Prostate Cancer	\$98,000
PC010270	Song	Jae	University of Pittsburgh	TRIAL-Based Radio-Gene Therapy for Prostate Cancer	\$98,000
PC010097	Sun	Jeonghoon	University of California	Engineering Protease-Specific Human Antibodies and Discovering Novel Serine Proteases Expressed in Prostate Cancer Using Phage Display	\$98,000
PC010383	Thomas	George	University of California, Los Angeles School of Medicine	PTEN Pathway in Prostate Cancer: Toward Its Targeted Therapy	\$97,932
PC010731	Xie	Xiaowei	Vancouver General Hospital	Experimental Treatment of Prostate Cancer Models with Rh2, an Isolated Ginsenoside Compound	\$71,108
PC010231	Ye	Xiangcang	Baylor College of Medicine	Regulable Gene Therapy for Prostate Cancer	\$98,000

FY01 Prostate Cancer Research Program Peer Reviewers

Peer Reviewers	Degree	Institution/Affiliation
Abcouwer, Steven F.	Ph.D.	University of New Mexico School of Medicine
Abdel-Mageed, Asim B.	D.V.M., Ph.D.	Tulane University Medical Center
Ahmed, Mansoor M.	Ph.D.	University of Kentucky Medical Center
Algan, Ozer	M.D.	Arizona Cancer Center
Arlen, Philip	M.D., Ph.D.	National Cancer Institute
Bachur, Nicholas R.	M.D., Ph.D.	University of Maryland Cancer Center
Bahnson, Robert R.	M.D.	Ohio State University College of Medicine
Balk, Steven P.	M.D., Ph.D.	Beth Israel Deaconess Medical Center
Barca, Richard A.		PAACT, Inc.
Basu, Alakananda	Ph.D.	University of North Texas Health Science Center
Berkowitz, Maynard		Carson Prostate Cancer Support Group
Bibbins, George L.		Malcolm Grow Hospital
Blair, William H.		US TOO International, Inc.
Blomberg, Bonnie B.	Ph.D.	University of Miami School of Medicine
Bodduluri, Radhika M.	Ph.D.	Accuray, Inc.
Bonavida, Benjamin	Ph.D.	University of California, Los Angeles School of Medicine
Brady-Kalnay, Susann M.	Ph.D.	Case Western Reserve University
Braunhut, Susan J.	Ph.D.	University of Massachusetts Lowell
Bridges, Kenneth Roland	M.D., Ph.D.	Harvard Medical School
Bright, Robert K.	Ph.D.	Chiles Research Institute, Franz Cancer Research Center
Britten, Richard	Ph.D.	University of Alberta, Cross Cancer Institute
Broccoli, Dominique	Ph.D.	Fox Chase Cancer Center
Brock, William A.	Ph.D.	University of Texas M.D. Anderson Cancer Center
Brodth, Pnina	Ph.D.	McGill University, Royal Victoria Hospital
Brown, Diane R.	Ph.D.	CULMA, Wayne State University
Brown, Milton L.	M.D., Ph.D.	University of Virginia
Brown, Richard F.		Florida Cancer Education Network
Brown, Terry R.	Ph.D.	Johns Hopkins University
Buatti, John M.	M.D.	University of Iowa Hospital and Clinics
Bublely, Glenn J.	M.D.	Harvard Institute of Medicine
Bushman, Wade A.	M.D., Ph.D.	Northwestern University School of Medicine
Buttyn, Ralph	Ph.D.	Columbia University
Callahan, Edward		Beverly Hospital
Calter, Michael	Ph.D.	University of Rochester
Carey, Robert		Men Coming Together
Carson, William E., III	M.D.	Ohio State University
Case, Larry D.	Ph.D.	Wake Forest University School of Medicine
Celis, Esteban	M.D., Ph.D.	Mayo Clinic
Cerhan, James Robert	M.D., Ph.D.	Mayo Clinic
Chai, Karl X.	Ph.D.	University of Central Florida

Peer Reviewers	Degree	Institution/Affiliation
Chambers, Timothy C.	Ph.D.	University of Arkansas for Medical Sciences
Chan, June M.	Sc.D.	University of California, San Francisco
Chang, Chawnshang	Ph.D.	University of Rochester Medical Center
Chatterjee, Bandana	Ph.D.	University of Texas Health Sciences Center at San Antonio
Chavez, Noel	Ph.D.	University of Illinois at Chicago
Chen, Timothy H.	M.D.	North Shore University Hospital
Chin, Khew-Voon	Ph.D.	University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School
Chrysogelos, Susan A.	Ph.D.	University of Michigan
Chung, Leland W.K.	Ph.D.	University of Virginia Health Sciences Center
Cidrowski, John A.	Ph.D.	National Institutes of Health, National Institute of Environmental Health Sciences
Clapp, William L.	M.D.	University of Florida College of Medicine
Clark, Andrew A.		Pendleton Prostate Cancer Support Group
Cohen, Harvey Joel	M.D., Ph.D.	Stanford University Medical School
Conover, Cheryl Ann	Ph.D.	Mayo Clinic
Conti, Claudio J.	D.V.M., Ph.D.	University of Texas M.D. Anderson Cancer Center
Corey, Eva	Ph.D.	University of Washington
Costello, Les C.	Ph.D.	University of Maryland Dental School, Baltimore College of Dental Surgery
Cunha, Gerald R.	Ph.D.	Department of Anatomy, University of California at San Francisco
Daar, Ira O.	Ph.D.	National Cancer Institute/Frederick
Davatzikos, Christos	Ph.D.	Johns Hopkins School of Medicine
Davis, Rodney	M.D.	Tulane University Health Sciences Center
Dawson, Laura Ann	M.D.	University of Michigan Hospitals Health System
Day, Mark L.	Ph.D.	University of Michigan
Denton, Maurice		US TOO International, Inc.
Diana, John N.	Ph.D.	Executive Secretary
Diefenbach, Michael A.	Ph.D.	Fox Chase Cancer Center
Dinney, Colin P.N.	M.D.	University of Texas M.D. Anderson Cancer Center
Djeu, Julie Y.	Ph.D.	University of South Florida College of Medicine
Dodd, Janice G.	Ph.D.	University of Manitoba
Dodson, John A.		Prostate Cancer Support Group-Greater Kingsport
Dong, Jin-Tang	Ph.D.	University of Virginia
Douglas, Joanne T.	Ph.D.	University of Alabama at Birmingham
Doxsey, Stephen J.	Ph.D.	University of Massachusetts Medical Center
El-Ashry, Dorraya	Ph.D.	Georgetown University Lombardi Cancer Center
Espinoza-Delgado, Igor J.	M.D.	National Institutes of Health, National Institute of Aging
Evans, Christopher P.	M.D., F.A.C.S.	University of California, Davis
Evans, Lemuel A.	Ph.D.	Executive Secretary
Evans, Sydney M.	V.M.D.	University of Pennsylvania
Ferguson, Samuel A.		100 Black Men of America, Inc.
Fleming, Quince D., Jr.		Southern Maryland Hospital; The Crawford Group, Inc.

Peer Reviewers	Degree	Institution/Affiliation
Foster, Barbara Ann	Ph.D.	Shadyside Medical Center
Fowler, Jackson E., Jr.	M.D.	University of Mississippi Medical Center
Franklin, Renty B.	Ph.D.	University of Maryland Dental School
Freeman, Vincent L.	M.D., M.P.H.	Loyola University Medical Center
Gann, Peter H.	M.D., Sc.D.	Northwestern University Medical School
Gardner, Thomas A.	M.D.	Wishard Health Service
Gerard, Claude		The American Prostate Society
Gimotty, Phyllis A.	Ph.D.	University of Pennsylvania School of Medicine
Gius, David R.	M.D., Ph.D.	Washington University
Gobel, Stephen	D.D.S.	Executive Secretary
Goins, William F.	Ph.D.	University of Pittsburgh School of Medicine
Goluboff, Erik	M.D.	Columbia-Presbyterian Medical Center
Gong, Michael C.	M.D., Ph.D.	Ohio State University Medical Center
Gonzalez-Villasenor, Irene	Ph.D.	Executive Secretary
Gopalkrishnan, Rahul V.	Ph.D.	Columbia University, College of Physicians and Surgeons
Groschen, Susan L. B. G.	Ph.D.	University of Southern California, Norris Cancer Center
Gruber, Stephen B.	M.D., Ph.D.	University of Michigan Health System
Gumerlock, Paul H.	Ph.D.	University of California, Davis Cancer Center
Gutwein, Fred W.		Memorial Sloan-Kettering Medical Center
Haas, Gabriel P.	M.D.	SUNY, Upstate Medical University
Haber, Roberta	Ph.D.	Executive Secretary
Hallman, D. Michael	Ph.D.	University of Texas, School of Public Health
Hamm, Robert MacGowan	Ph.D.	University of Oklahoma Health Science Center
Han, David K.	Ph.D.	University of Connecticut Health Center
Hannon, Gregory J.	Ph.D.	Cold Spring Harbor Laboratory
Harris, Robert D	M.D.	Dartmouth Hitchcock Medical Center
Haut, Michael J.	M.D.	Pennsylvania Hospital
Hayward, Simon W.	Ph.D.	Vanderbilt University School of Medicine
Helferich, William G.	Ph.D.	University of Illinois
Hellstrom, Ingegerd E.	M.D., Ph.D.	University of Washington
Helman, Sandy I.	Ph.D.	University of Illinois at Urbana-Champaign
Hemstreet, George P., III	M.D., Ph.D.	University of Oklahoma
Hendrich, Suzanne	Ph.D.	Iowa State University
Ho, Shuk-Mei	Ph.D.	University of Massachusetts Medical School
Hope, George S.		US TOO Prostate Cancer Survivor Support Group
Horowitz, Jonathan M.	Ph.D.	North Carolina State University, College of Veterinary Medicine
Hsieh, Jer-Tsong	Ph.D.	University of Texas Southwestern Medical Center at Dallas
Humm, John Laurence	Ph.D.	Memorial-Sloan Kettering Medical Center
Huppi, Konrad E.	Ph.D.	National Institutes of Health, National Cancer Institute
Hurwitz, Arthur A.	Ph.D.	SUNY Upstate Medical Center
Ittmann, Michael M.	M.D., Ph.D.	Houston VA Medical Center
Jackson, Aaron G.	M.D.	Howard University Hospital
Jacobberger, James W.	Ph.D.	Case Western Reserve University, Cancer Research Center

Peer Reviewers	Degree	Institution/Affiliation
Jacobson, Kenneth A.	Ph.D.	National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
Jarrard, David F.	M.D.	University of Wisconsin
Jeng, Meei-Huey	Ph.D.	Indiana University
Johnson, Carolyn C.	Ph.D.	Tulane University
Joy, Daniel W.		US TOO Prostate Cancer Survivor Support Group
Kao, Chinghai	Ph.D.	Indiana University
Kaplan, Alan M.	Ph.D.	University of Kentucky School of Medicine
Kasl, Stanislav V.	Ph.D.	Yale University School of Medicine
Kasper, Susan	Ph.D.	Vanderbilt Medical Center North
Keefer, Garrett V.	Ph.D.	Executive Secretary
Keller, Evan T.	D.V.M., Ph.D.	University of Michigan
Keller, Jonathan R.	Ph.D.	National Cancer Institute, Frederick Cancer Research and Development Center
Kendall, Fred		Resurrection Baptist Church
Keri, Ruth A.	Ph.D.	Case Western Reserve University
Kern, Francis G.	Ph.D.	Southern Research Institute
Khalkhali-Ellis, Zhila	Ph.D.	University of Iowa
Klinge, Carolyn M.	Ph.D.	University of Louisville School of Medicine
Knepper, Janice E.	Ph.D.	Villanova University
Kothari, Manish	Ph.D.	Synarc
Kowal, Boyd		Georgetown University Hospital
Kuchta, Robert D.	Ph.D.	University of Colorado at Boulder
Kulp, Donald D.		Pennsylvania Prostate Cancer Coalition (PPCC)
Kurt, Robert A.	Ph.D.	Lafayette College
Kwon, Eugene D.	M.D.	Loyola University Medical Center, Cardinal Bernardin Cancer Center
Kyprianou, Natasha	Ph.D.	University of Maryland School of Medicine
Labrie, Claude	M.D., Ph.D.	Laval University Medical Center (CHUL)
Lamb, Dolores J.	Ph.D.	Baylor College of Medicine
Latimer, Jean J.	Ph.D.	University of Pittsburgh School of Medicine, Magee Woman's Research Institute
Leong, Lucille A.	M.D.	City of Hope National Medical Center
Leslie, J. Paul, Jr.		Ochsner Cancer Institute
Levine, Alice C.	M.D.	Mount Sinai School of Medicine
Lewis, Lionel D.	M.D.	Dartmouth Medical Center
Liebhaber, Stephen A.	M.D.	University of Pennsylvania, Howard Hughes Medical Institute
Lin, Sue-Hwa	Ph.D.	University of Texas M.D. Anderson Cancer Center
Lingrel, Jerry B.	Ph.D.	University of Cincinnati College of Medicine
Link, Charles J., Jr.	M.D.	Human Gene Therapy Research Institute
Lipkus, Isaac Marcelo	Ph.D.	Duke University Medical Center
Liu, Bo	Ph.D.	University of Pittsburgh Cancer Institute
Liu, Brian C.S.	Ph.D.	Brigham and Women's Hospital
Loda, Massimo	M.D.	Dana Farber Cancer Institute

Peer Reviewers	Degree	Institution/Affiliation
Loeb, Virgil		American Cancer Society
Lokeshwar, Bal L.	Ph.D.	University of Miami School of Medicine
Lowe, Robert A.		US TOO Prostate Cancer Support Group
Lowery, Dolores Lopez	M.S.	Lowery Associates
Lubaroff, David Martin	Ph.D.	University of Iowa College of Medicine
Lum, Clark K.	Ph.D.	Executive Secretary
Macoska, Jill A.	Ph.D.	University of Michigan
Magnuson, Nancy S.	Ph.D.	Washington State University
Maizels, Nancy	Ph.D.	University of Washington Medical School
Mansfield, Carl M.	M.D., Sc.D.	University of Maryland School of Medicine
Marcus, Aaron J.	M.D.	Weill Medical College of Cornell University
Marengo, Susan Ruth	Ph.D.	Case Western Reserve University
Marfyak, Jan		Pennsylvania Prostate Cancer Coalition
Mason, Ralph P.	Ph.D.	University of Texas Southwestern Medical Center
Matthews, Alicia K.	Ph.D.	University of Chicago
Mayo, Matthew S.	Ph.D.	University of Kansas Medical Center
McConkey, David J.	Ph.D.	University of Texas M.D. Anderson Cancer Center
McCormack, John J.	Ph.D.	University of Vermont
McCullough, Charles E.	M.S.	Georgetown University Hospital
McDonald, Vincent P.		Center for Prostate Disease Research
McDonnell, Timothy J.	M.D., Ph.D.	University of Texas M.D. Anderson Cancer Center
McElhiney, George H.		Metrowest Cancer Center
Meadows, Gary G.	Ph.D.	Washington State University College of Pharmacy, Cancer Prevention and Research Center
Medrano, Estela E.	Ph.D.	Baylor College of Medicine
Mehrmann, Louis W.		American Cancer Society
Mehta, Rajeshwari R.	Ph.D.	University of Illinois Medical Center
Meier, Kathryn Elaine	Ph.D.	Medical University of South Carolina
Meltzer, Carolyn Cidis	M.D.	University of Pittsburgh Medical Center
Messing, Edward M.	M.D.	University of Rochester
Miller, Donald M.	M.D., Ph.D.	James Graham Brown Cancer Center
Mittler, Robert S.	Ph.D.	Emory University, Emory Vaccine Center
Moon, Peter C.		US TOO International, Inc.
Morris, Donald G.	M.D., Ph.D.	University of Calgary
Morris, Patricia L.	Ph.D.	Rockefeller University
Mukherji, Bijay	M.D.	University of Connecticut
Mulhern, Sally Ann	Ph.D.	Executive Secretary
Nanda, Navreet	Ph.D.	University of Illinois at Chicago
Narayan, Satya	Ph.D.	University of Florida Shands Cancer Center
Nelson, Colleen	Ph.D.	Jack Bell Research Centre
Nelson, Mark A.	Ph.D.	Arizona Cancer Center
Nelson, Peter S.	M.D.	Fred Hutchinson Cancer Research Center
Neuhausen, Susan L.	Ph.D.	University of Utah
Newhouse, Jeffrey H.	M.D.	Columbia University, College of Physicians and Surgeons

Peer Reviewers	Degree	Institution/Affiliation
Nielsen, Harald C.		US TOO, Peoria
Nishimura, Michael I.	Ph.D.	University of Chicago Medical Center
Nordeen, Steven K.	Ph.D.	University of Colorado
Nowak, Norma J.	Ph.D.	University of New York
Nutter, John E.	Ph.D.	Executive Secretary
O'Donnell, Robert T.	M.D., Ph.D.	University of California, Davis
O'Rourke, Maureen E.	Ph.D.	University of North Carolina, Greensboro
Oesterreich, Steffi	Ph.D.	Baylor College of Medicine, Breast Cancer Center
Okunieff, Paul		University of Rochester
Ove, Peter	Ph.D.	Executive Secretary
Pachciarz, Judith Ann	M.D., Ph.D.	Martin Luther King, Jr./Charles R. Drew Medical Center
Palos, William		US TOO International, Inc.
Pandita, Tej Krishan	Ph.D.	Columbia University
Papa, Christopher M.		US TOO International, Inc.
Parra-Medina, Deborah	Ph.D., M.P.H.	University of South Carolina
Passaniti, Antonino	Ph.D.	University of Maryland, Greenbaum Cancer Center
Pasternack, Gary R.	M.D., Ph.D.	Johns Hopkins University School of Medicine
Peehl, Donna M.	Ph.D.	Stanford University Medical Center
Pence, Barbara C.	Ph.D.	Texas Tech University Health Sciences Center
Penn, Linda J.Z.	Ph.D.	Ontario Cancer Institute
Penning, Trevor M.	Ph.D.	University of Pennsylvania
Perez-Stable, Carlos	Ph.D.	University of Miami School of Medicine
Perz, Catherine A.	Ph.D.	University of Houston, Victoria
Pizer, Ellen Sarah	M.D., Ph.D.	Johns Hopkins Bayview Medical Center
Plante, Mark K	M.D.	University of Vermont
Platz, Elizabeth A.	Sc.D., M.P.H.	Johns Hopkins School of Hygiene and Public Health
Plymate, Stephen R.	M.D.	University of Washington
Potter, Philip M.	Ph.D.	St. Jude Children's Hospital
Prochownik, Edward Victor	M.D., Ph.D.	Children's Hospital of Pittsburgh
Radinsky, Robert	Ph.D.	Amgen, Inc.
Rane, Stanley G.	Ph.D.	Purdue University
Rangnekar, Vivek M.	Ph.D.	University of Kentucky
Rebbeck, Timothy R.	Ph.D.	University of Pennsylvania
Reddi, A. Hari	Ph.D.	University of California, Davis
Rennie, Paul S.	Ph.D.	Vancouver General Hospital
Rinker-Schaeffer, Carrie W.	Ph.D.	University of Chicago
Robbins, Michael E.	Ph.D.	University of Iowa
Roberts, Charles T., Jr.	Ph.D.	Oregon Health Sciences University
Roe, Terrence M.		US TOO International, Inc.
Roppolo, Louis J.		US TOO International, Inc.
Ross, Jeff	M.D.	University of Wisconsin, McArdle Laboratory
Rothstein, Jay L.	Ph.D.	Thomas Jefferson University
Roy-Burman, Pradip	Ph.D.	University of Southern California

Peer Reviewers	Degree	Institution/Affiliation
Rubin, Mark A.	M.D.	University of Michigan
Rucker, Hubert K., Jr.	Ph.D.	Meharry Medical College
Sadar, Marianne D.	Ph.D.	British Columbia Cancer Agency
Samei, Ehsan	Ph.D.	Duke University
Sant'Angelo, Derek B.	Ph.D.	Memorial Sloan-Kettering Cancer Center
Sartor, A. Oliver	M.D.	Louisiana State University Medical School
Saw, Cheng B.	Ph.D.	University of Nebraska Medical Center
Schiff, Peter B.	M.D., Ph.D.	New York Presbyterian Hospital
Schrader, William T.	Ph.D.	XenoPharm, Inc.
Schulze-Gahmen, Ursula	Ph.D.	Lawrence Berkeley National Laboratory
Secrist, John A., III	Ph.D.	Southern Research Institute
Sehgal, Inder	D.V.M., Ph.D.	North Dakota State University College of Pharmacy
Seibert, James Anthony	Ph.D.	University of California, Davis Medical Center
Sellers, Thomas A.	Ph.D.	Mayo Clinic
Sens, Donald A.	Ph.D.	University of West Virginia
Shain, Sydney A.	Ph.D.	University of Texas Health Science Center
Sheffield, Alonzo D.		Men Coming Together
Sheng, Shijie	Ph.D.	Wayne State University School of Medicine
Shi, YuFang	D.V.M., Ph.D.	American Red Cross
Sholes, Westley		California Prostate Cancer Coalition
Siegel, Gene Philip	M.D., Ph.D.	University of Alabama at Birmingham
Sikes, Robert A.	Ph.D.	University of Virginia Health System
Simkins, John C.		US TOO International, Inc.
Sloboda, Walter	M.A.	Executive Secretary
Smith, Allen N.	M.S.	Developmental Progress, Inc.
Smith, Gary J.	Ph.D.	University of North Carolina at Chapel Hill
Smyth, Mary J. (Miriam)	Ph.D.	University of Maryland, Baltimore County, VA Medical Center
Song, Chang W.	Ph.D.	University of Minnesota School of Medicine
Staerz, Uwe	M.D., Ph.D.	National Jewish Medical and Research Center
Stafford, Patrick M.	Ph.D.	Radiation Oncology Services
Stamenkovic, Ivan	M.D.	Massachusetts General Hospital
Stierman, Joseph W., Jr.		Walter Reed Army Medical Center, US TOO
Stockand, James D.	Ph.D.	University of Texas Health Sciences Center
Stoianovici, Dan	Ph.D.	Johns Hopkins University
Strawther, Dexter, III		Prostate Forum of Fullerton
Strobl, Jeannine	Ph.D.	West Virginia University Health Sciences Center
Sucato, Justin F.		US TOO of Western New York
Sun, LuZhe	Ph.D.	University of Texas Health Science Center
Sun, Zijie	Ph.D.	Stanford University Medical Center
Taneja, Samir S.	M.D.	New York University Medical Center
Tang, Dean G.	M.D., Ph.D.	University of Texas M.D. Anderson Cancer Center
Teague, Robert		US TOO International, Inc.
Thomas, Peter	Ph.D.	Boston University School of Medicine

Peer Reviewers	Degree	Institution/Affiliation
Thomas, Regi	Ph.D.	Bracco Research USA
Tofilon, Philip	Ph.D.	National Cancer Institute
Tornai, Martin P.	Ph.D.	Duke University
Trevor, Katrina T.	Ph.D.	Arizona Cancer Center
Tuszynski, George P.	Ph.D.	MCP Hahnemann University
Umbreit, Jay N.	M.D., Ph.D.	University of South Alabama
Underhill, Charles B.	Ph.D.	Georgetown University Medical Center
Valerie, Carl Kristoffer	Ph.D.	Medical College of Virginia
Van Tassel, Roger A.		US TOO International, Inc.
Vazquez, Manuel		US TOO International, Inc.
Vieweg, Johannes W.G.	M.D.	Duke University Medical Center
Wang, Zhou	Ph.D.	Northwestern University Medical School
Ware, Joy L.	Ph.D.	Virginia Commonwealth University, Medical College of Virginia
Warlick, William B., Jr.	M.D.	Walter Reed Army Medical Center
Weeks, James		US TOO Prostate Cancer Survivor Support
Welch, Danny R.	Ph.D.	Pennsylvania State University, Jake Gittlien Cancer Research Institute
Werness, Bruce A.	M.D.	Inova Fair Oaks Hospital
Wiegman, James C.		Cancer Service of Allen County
Williams, Briana Jill	Ph.D.	Louisiana State University Medical Center
Williford, Donald E.		Walter Reed Army Medical Center
Wilson, Elizabeth M.	Ph.D.	University of North Carolina at Chapel Hill
Winters, Stephen J.	M.D.	University of Louisville Health Sciences Center
Wolgemuth, Debra J.	Ph.D.	Columbia University, College of Physicians and Surgeons
Woloschak, Gayle E.	Ph.D.	Argonne National Laboratory
Wood, F. Edward, Jr.	Ph.D.	Sullivan and Associates
Woolfenden, James M.	M.D.	University of Arizona
Workman, Derek H.		Prostate Cancer Support Association
Wright, William C.		Prostate Forum of Fullerton, California
Xiao, Zhi-Xiong (Jim)	Ph.D.	Boston University School of Medicine
Yeh, Shuyuan	Ph.D.	University of Rochester
Young, Charles Y.F.	Ph.D.	Mayo Clinic Foundation
Young, M. Rita I.	Ph.D.	Hines VA Hospital
Zebovitz, Eugene	Ph.D.	Executive Secretary
Zhang, Ming	Ph.D.	Baylor College of Medicine
Zhang, Xiao-Kun	Ph.D.	Burnham Institute
Zheng, Yixian	Ph.D.	Carnegie Institution of Washington
Zimmer, Stephen G.	Ph.D.	University of Kentucky Medical Center
Zwicker, Robert Dennis	Ph.D.	University of Kentucky Medical Center

**Fiscal Year 2001 Prostate Cancer Research Program
Integration Panel (IP) Members**

IP Members	Degree	Institution/Affiliation
Olsson, Carl (Chair)	M.D.	Columbia University
Adams-Campbell, Lucile	Ph.D.	Howard University Cancer Center
Carey, Thomas	Ph.D.	University of Michigan
Coffey, Donald (Executive Committee Member)	Ph.D.	The Johns Hopkins Hospital
DeVere White, Ralph (Chair-Elect)	M.D.	University of California, Davis Medical Center
Dreicer, Robert	M.D.	The Cleveland Clinic Foundation
Dyer, Winston		CaP CURE
Howe, Richard (Executive Committee Member)	Ph.D.	National Prostate Cancer Coalition
Kantoff, Philip	M.D.	Dana-Farber Cancer Institute
Lieberman, Ronald	M.D.	National Cancer Institute
Liebert, Monica	Ph.D.	American Urological Association
Morton, Ronald, Jr.	M.D.	Baylor College of Medicine
Prins, Gail	Ph.D.	University of Illinois at Chicago
Roach, Mack, III	M.D.	University of California, San Francisco
Soule, Howard	Ph.D.	CaP CURE
Vogelzang, Nicholas	M.D.	University of Chicago
von Eschenbach, Andrew (Chair-Emeritus)	M.D.	University of Texas M.D. Anderson Cancer Center
Waldman, Frederic	M.D., Ph.D.	University of California, San Francisco

**Fiscal Year 2001 Prostate Cancer Research Program
Ad Hoc Programmatic Reviewers**

Ad Hoc Reviewers	Degree	Institution/Affiliation
Fisher, Susan	Ph.D.	University of Rochester
Schover, Leslie	Ph.D.	University of Texas, M.D. Anderson Cancer Center
Vijayakumar, Srinivasan	M.D., DMRT	University of Illinois at Chicago
Taylor, Jeremy	Ph.D.	University of Michigan Comprehensive Cancer Center
Williams, James		US TOO International, Inc. (Consumer)

Glossary of Terms

Health Disparity Research – Prostate Scholar Awards (HDR-PSA): The HDR-PSA are intended to encourage investigators at the assistant professor or equivalent level to focus their research efforts on the disparate burden of prostate cancer in African Americans. These awards will require the active involvement of a collaborator who is an established prostate cancer researcher, and a statement of institutional commitment that the institution will foster the applicant's prostate cancer research career. The ultimate goal of these awards is to resolve the disparity in prostate cancer incidence, morbidity, and mortality between African Americans and other ethnic groups. All investigators submitting proposals to this award must demonstrate a connection to, or effectiveness in working with the African American community. Such demonstration might include previous experience working with the African American population and/or demonstrated cultural ties to the African American community.

Health Disparity Training – Prostate Scholar Awards (HDT-PSA): The HDT-PSA are intended to provide investigators in the early stages of their careers with training opportunities that focus on the disparate burden of prostate cancer in African Americans. The guidance of a designated mentor and the active involvement of an established prostate cancer researcher are requirements for this award. The ultimate goal of these awards is to resolve the disparity in prostate cancer incidence, morbidity, and mortality between African Americans and other ethnic groups. Investigators submitting proposals to this award must demonstrate a connection to, or effectiveness in working with the African American community. Such demonstration might include previous experience working with the African American population and/or demonstrated cultural ties to the African American community. Under this award mechanism, investigators may apply for Predoctoral Traineeships, Postdoctoral Traineeships, or Postresidency Traineeships.

Historically Black Colleges and Universities (HBCU) Collaborative Partnership Awards: The HBCU Collaborative Partnership Awards are institutionally based awards intended to intensify the commitment of the prostate cancer research community to investigate the disparate burden of prostate cancer in African American men. To effectively address this issue, these awards are directed at HBCU as a means to increase the number of HBCU scientists who are trained as prostate cancer researchers. The major goal of this award is to establish stable, long-term partnerships between an applicant HBCU and a collaborating non-HBCU institution to (1) provide mentorship and collaborative research opportunities for HBCU scientists, clinicians, and trainees; (2) develop, promote, and sustain independent, competitive research and training programs at the HBCU; and (3) increase the number of HBCU investigators focused on prostate cancer research. Strong institutional commitments are required from both the HBCU and collaborating institution.

Idea Development Awards: The intent of Idea Development Awards is to encourage innovative approaches to prostate cancer research from established prostate cancer investigators and those investigators who are at, or above the level of assistant professor or equivalent who want to move into the prostate cancer field. Idea Development Award research should represent the start of something new, creating or introducing a unique or unusual approach to the study of prostate cancer. This research may represent a new paradigm, challenge existing paradigms, or look at an

existing problem from a new perspective. All Idea Development proposals must include preliminary data.

New Investigator Award: The intent of New Investigator Awards is to promote and reward innovative ideas and technology from investigators in the early phases of their careers, as well as established investigators new to prostate cancer research who have little or no preliminary data in prostate cancer. A new investigator is defined as an independent investigator with access to appropriate research facilities. The proposed studies may be untested but have a high probability of revealing new avenues of investigation. Although this research is inherently risky in nature and does not require preliminary or pilot data, these proposals nonetheless should be based on a sound scientific rationale that is established through a critical review and analysis of the literature and logical reasoning.

Postdoctoral Traineeship Award: The intent of Postdoctoral Traineeship Awards is to enable recent doctoral degree graduates with limited postdoctoral experience (i.e., 3 years or less at the time of proposal submission) either to extend ongoing research related to prostate cancer, or to broaden the scope of their research to include work relevant to prostate cancer under the guidance of a designated mentor. Eligible applicants must have successfully defended a doctoral thesis and completed all academic requirements at the time of award negotiation.

Prostate Cancer Clinical Trial Awards: The intent of the Prostate Cancer Clinical Trial Awards (a.k.a. Clinical Trial Awards) is to fund prospective Phase I or Phase II clinical trials in the areas of prostate cancer therapy, diagnosis, detection, and prevention. These awards are intended to focus on clinical trials of new therapeutics or treatments rather than refining administration of existing therapies (e.g., optimizing timing or dosage regimens). Proposals must include a strategy to collect correlative data that addresses the underlying mechanisms of clinical efficacy. Clinical Trial Awards are for the support of projects that are likely to have a major impact on the prevention, diagnosis, or treatment of prostate cancer by applying promising and well-founded laboratory or other preclinical findings to the care of patients with prostate cancer. Applicants must include data to support the feasibility of their hypotheses and approaches, along with a plan to conduct a prospective clinical trial or study. The inclusion of a clear experimental and appropriately powered statistical plan to perform a prospective clinical trial or study is a requirement. The clinical trial proposed as part of the submission must be ready for patient enrollment upon receipt of funds. These awards are intended to support both new and established scientists across a broad spectrum of disciplines.

Prostate Cancer Consortium Awards: The intent of the Prostate Cancer Consortium Awards (a.k.a. Consortium Awards) is to develop a major, coordinated, goal/product-driven research effort that involves the nation's leading prostate cancer researchers and focuses on an overarching problem relevant to the prevention, detection, diagnosis, treatment, or cure of prostate cancer. Unlike other mechanisms, the Consortium Award will be executed through two separate awards, the Prostate Cancer Consortium Development Award in FY01 and the Prostate Cancer Consortium Award in FY02. The Consortium Development Award is intended to provide support to establish the necessary collaborations and develop the preliminary infrastructure, including a coordination core that will provide the foundation for a Consortium Award. One product of the Consortium Development Award will be the submission of a

proposal for a Consortium Award in the spring of 2002. Consortium Development Award funds can cover administrative support including salary, meetings and related travel among consortium participants, database generation and software development, purchase of computers, design of web sites, teleconferences, and other costs directly associated with planning and developing the consortium. However, the funds may not be used to support laboratory research.